Human Umbilical Cord Mesenchymal Stromal Cell Transplantation in Myocardial Ischemia (HUC-HEART Trial). A Study Protocol of a Phase 1/2, Controlled and Randomized Trial in Combination with Coronary Artery Bypass Grafting
Stem Cell Reviews and Reports · 2015-10 · 11 (5) · 752-760
DOI: 10.1007/s12015-015-9601-0 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Stem Cell Reviews and Reports, online erschienen am 28.06.2015. Verfasst von Alp Can und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Histology and Embryology, Laboratory for Stem Cells and Reproductive Cell Biology, Ankara University School of Medicine, Ankara, Turkey…. Die Arbeit wurde bisher 40-mal zitiert (Crossref) und nennt 56 Literaturangaben.
Abstract (Originalsprache)
Mesenchymal stem cells (MSCs), which may be obtained from the bone marrow, have been studied for more than a decade in the setting of coronary artery disease (CAD). Adipose tissue-derived MSCs have recently come into focus and are being tested in a series of clinical trials. MSC-like cells have also been derived from a variety of sources, including umbilical cord stroma, or HUC-MSCs. The HUC-HEART trail (ClinicalTrials.gov Identifier: NCT02323477) is a phase 1/2, controlled, multicenter, randomized clinical study of the intramyocardial delivery of allogeneic HUC-MSCs in patients with chronic ischemic cardiomyopathy. A total of 79 patients (ages 30-80) with left ventricle ejection fractions ranging between 25 and 45% will be randomized in a 2:1:1 pattern in order to receive an intramyocardial injection of either HUC-MSCs or autologous bone marrow-derived mononuclear cells (BM-MNCs) in combination with coronary arterial bypass grafting (CABG) surgery. The control group of patients will receive no cells and undergo CABG alone. Human HUC-MSCs will be isolated, propagated and banked in accordance with a cGMP protocol, whereas the autologous BM-MNCs will be isolated via aspiration from the iliac crest and subsequently process in a closed-circuit cell purification system shortly before cell transplantation. The cell injections will be implemented in 10 peri-infarct areas. Baseline and post-transplantation outcome measures will be primarily utilized to test both the safety and the efficacy of the administered cells for up to 12 months.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Histology and Embryology, Laboratory for Stem Cells and Reproductive Cell Biology, Ankara University School of Medicine, Ankara, Turkey, alpcan@medicine.ankara.edu.tr.
Zitieren
APA
Can, A., Ulus, A. T., Cinar, O., Topal Celikkan, F., Simsek, E., Akyol, M., Canpolat, U., Erturk, M., Kara, F., & Ilhan, O. (2015). Human Umbilical Cord Mesenchymal Stromal Cell Transplantation in Myocardial Ischemia (HUC-HEART Trial). A Study Protocol of a Phase 1/2, Controlled and Randomized Trial in Combination with Coronary Artery Bypass Grafting. Stem Cell Reviews and Reports, 11(5), 752-760. https://doi.org/10.1007/s12015-015-9601-0
Vancouver
Can A, Ulus AT, Cinar O, Topal Celikkan F, Simsek E, Akyol M, et al. Human Umbilical Cord Mesenchymal Stromal Cell Transplantation in Myocardial Ischemia (HUC-HEART Trial). A Study Protocol of a Phase 1/2, Controlled and Randomized Trial in Combination with Coronary Artery Bypass Grafting. Stem Cell Reviews and Reports. 2015;11(5):752-760. doi:10.1007/s12015-015-9601-0
BibTeX
@article{Can2015,
author = {Can, Alp and Ulus, Ahmet Tulga and Cinar, Ozgur and Topal Celikkan, Ferda and Simsek, Erdal and Akyol, Mesut and Canpolat, Ugur and Erturk, Murat and Kara, Fadil and Ilhan, Osman},
title = {Human Umbilical Cord Mesenchymal Stromal Cell Transplantation in Myocardial Ischemia (HUC-HEART Trial). A Study Protocol of a Phase 1/2, Controlled and Randomized Trial in Combination with Coronary Artery Bypass Grafting},
journal = {Stem Cell Reviews and Reports},
year = {2015},
volume = {11},
number = {5},
pages = {752--760},
doi = {10.1007/s12015-015-9601-0}
}
EUVIMED